Crucell NV

Crucell NV is a global biopharmaceutical company headquartered in Leiden, the Netherlands. With over 1,300 employees, the company operates offices in various countries including China, Indonesia, Italy, Korea, Malaysia, Spain, Sweden, Switzerland, the UK, the USA, and Vietnam. Crucell NV is listed on NYSE Euronext and NASDAQ (CRXL) and the SIX Swiss Exchange (CRX). Crucell focuses on developing and marketing products to combat major global health threats. Their expertise lies in fighting infectious diseases through a diverse range of product candidates. These include flu-mAb, an antibody effective against a broad spectrum of influenza virus strains, tuberculosis and malaria vaccines, and a rabies monoclonal antibody combination. All these products are produced using their proprietary PER.C6® human-cell technology. Crucell currently markets vaccines for pediatric, travel & endemic, and respiratory diseases, positioning itself as the largest independent vaccine company worldwide. Crucell's success is driven by its innovative technologies and a dedicated team of researchers and developers. The company emphasizes its commitment to innovation, reflected in its robust research & development pipeline with promising product candidates in both pre-clinical and clinical development stages. Crucell NV can be reached via their website at crucell.com.